SCHEMBL1304259

SCHEMBL1304259

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)C2O)c(=O)[nH]1

nearest known ligand 0.81

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.81
NT5E P21589 1/20 0.76
KRAS P01116 2/20 0.76
FUT5 Q11128 1/20 0.75
P2RX3 P56373 2/20 0.71
P2RY6 Q15077 2/20 0.71
P2RY2 P41231 1/20 0.71
P2RY4 P51582 1/20 0.71
P2RY1 P47900 4/20 0.68
ENPP1 P22413 2/20 0.68
P2RX1 P51575 1/20 0.68
P2RY11 Q96G91 1/20 0.68
P2RX4 Q99571 1/20 0.68
P2RY12 Q9H244 1/20 0.66
IMPDH2 P12268 5/20 0.65
IMPDH1 P20839 1/20 0.65
DCPS Q96C86 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gtp SCHEMBL18271799 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL3333959 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL376140 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL18784960 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL376139 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL1304258 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL19691775 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
SCHEMBL2593095 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL5809658 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3
Gtp SCHEMBL17367368 1.00 TGM2 (0.81) TGM2NT5EKRASFUT5P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025231164-A2 ENGINEERED PLANT MICROORGANISMS FOR RNAi DELIVERY AND USES THEREOF ROBIGO, INC. (US) 2025-11-06 WO claimed
US-20150366777-A1 COMBINATION OF SKIN PROTECTION AGAINST DAMAGES CAUSED BY INFRARED RADIATION HYPERMARCAS S.A. (BR) 2015-12-24 US claimed
US-6562801-B1 PpGpp and pppGpp as immunomodulatory agents BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-05-13 US claimed
US-20030039657-A1 Inducible vaccines BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-02-27 US claimed
WO-2000062817-A2 INDUCIBLE VACCINES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-10-26 WO claimed
WO-2000062803-A2 ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-10-26 WO claimed
US-20260128119-A1 SCREENING METHODS FOR ACINETOBACTER BAUMANNII SPOT ENZYME MODULATORS Université Libre de Bruxelles (BE) 2026-05-07 US disclosed
EP-4696775-A1 NOVEL VARIANT OF (P)PPGPP SYNTHETASE AND METHOD FOR PRODUCING 5?-INOSINIC ACID USING SAME Daesang Corporation (KR) 2026-02-18 EP disclosed
WO-2025231164-A2 ENGINEERED PLANT MICROORGANISMS FOR RNAi DELIVERY AND USES THEREOF ROBIGO, INC. (US) 2025-11-06 WO disclosed
US-20250297298-A1 FERMENTATION PROCESS INTENDED TO PRODUCE METABOLITES WITH EPIGENETIC PROPERTIES USING BACTERIA EVOLVED IN THE EXTREME CONDITIONS OF SPACE INNOVATION LABO SCIENCES CO LTD (JP) 2025-09-25 US disclosed
EP-4605090-A1 SCREENING METHODS FOR ACINETOBACTER BAUMANNII SPOT ENZYME MODULATORS Université Libre de Bruxelles (BE) 2025-08-27 EP disclosed
US-20250223542-A1 MODIFIED MICROALGAE FOR ENHANCED PHOSPHATE UPTADE INVOLVING OVEREXPRESSION OF PSR1 AND OPTIONALLY UNDEREXPRESSION OF PTC1 INSTITUTE OF AGRICULTURAL RESOURCES AND REGIONAL PLANNING OF THE CHINESE ACADE (CN) 2025-07-10 US disclosed
CN-118360353-B Method for improving thaxtomin A yield through Streptomyces scab relA gene 安徽农业大学 2025-04-08 CN disclosed
US-5998159-A MEASURING ACCUMULATION OF BACTERIA RIBOGENE, INC. (US) 1999-12-07 US disclosed
WO-1999051766-A1 METHODS FOR PRODUCING LIBRARIES OF EXPRESSIBLE GENE SEQUENCES INVITROGEN CORPORATION (US) 1999-10-14 WO disclosed
WO-1999051620-A1 LIBRARIES OF EXPRESSIBLE GENE SEQUENCES INVITROGEN CORPORATION (US) 1999-10-14 WO disclosed
WO-1998035054-A1 METHODS FOR SCREENING FOR ANTIBIOTICS RIBOGENE, INC. (US) 1998-08-13 WO disclosed
US-4152209-A CULTIVATING A STRAIN OF STREPTOMYCES OR STREPTOVERTICILLIUM SANRAKU-OCEAN CO., LTD. (JP) 1979-05-01 US disclosed
US-4141972-A Purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and processes for their preparation SANRAKU-OCEAN CO., LTD. (JP) 1979-02-27 US disclosed
US-4059487-A Purine nucleoside 5'-phosphate (mono, di or tri) 3'(2')-diphosphates and processes for their preparation SANRAKU-OCEAN CO., LTD. (JA) 1977-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260128119-A1 SCREENING METHODS FOR ACINETOBACTER BAUMANNII SPOT ENZYME MODULATORS STUB1, PPME1, BPGM TGM2 938/4885NT5E 2350/4885KRAS 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.